Thioredoxin system - A novel therapeutic target

General Physiology and Biophysics

Volumn 34, Issue 3, 2015, Pages 221-233

  Koháryová, Michaela ^a   Kollárová, Marta ^a  

^a Faculty of Natural Sciences   (Slovakia)

Author keywords

Inhibitors; Oxidative stress; Thioredoxin system

Indexed keywords

ARSENIC TRIOXIDE; AURANOFIN; CATECHIN; CISPLATIN; CURCUMIN; DNA POLYMERASE; EBSELEN; FLAVONOID; GADOLINIUM TEXAPHYRIN; GLUTAREDOXIN; HYPERICIN; METHYLMERCURY; MYRICETIN; NSC 131233; PELARGONIDIN; PSEUDOHYPERICIN; QUERCETIN; QUINONE DERIVATIVE; TAXIFOLIN; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; HELICOBACTER PYLORI; HUMAN; MICROORGANISM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS;

EID: 84941059220     PISSN: 02315882     EISSN: 13384325     Source Type: Journal    
DOI: 10.4149/gpb_2015006     Document Type: Article

References (129)

1. Aggarwal B. B., Kumar A., Bharti A. C. (2003): Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363-398
2. Akbar M. A., Chatterjee N. S., Sen P., Debnath A., Pal A., Bera T., Das P. (2004): Genes induced by a high-oxygen environment in Entamoeba histolytica. Mol. Biochem. Parasitol. 133, 187-196 http://dx.doi.org/10.1016/j.molbiopara.2003.10.006
3. Andersson M. (1996): NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase: implication for a protective mechanism against NK-lysin cytotoxicity. J. Biol. Chem. 271, 10116-10120 http://dx.doi.org/10.1074/jbc.271.17.10116
4. Arias D. G., Gutierrez C. E., Iglesias A. A., Guerrero S. A. (2007): Thioredoxin-linked metabolism in Entamoeba histolytica. Free Radic. Biol. Med. 42, 1496-1505 http://dx.doi.org/10.1016/j.freeradbiomed.2007.02.012
5. Ariyanayagam M. R., Fairlamb A. H. (1999): Entamoeba histolytica lacks trypanothione metabolism. Mol. Biochem. Parasitol. 103, 61-69 http://dx.doi.org/10.1016/S0166-6851(99)00118-8
6. Arnér E. S., Holmgren A. (2000): Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102-6109 http://dx.doi.org/10.1046/j.1432-1327.2000.01701.x
7. Arnér E. S., Holmgren A. (2006): The thioredoxin system in cancer. Semin Cancer Biol. 16, 420-426 http://dx.doi.org/10.1016/j.semcancer.2006.10.009
8. Baker L. M., Raudonikiene A., Hoffman P. S., Poole L. B. (2001): Essential thioredoxindependent peroxiredoxin system from Helicobacter pylori: genetic and kinetic characterization. J. Bacteriol. 183, 1961-1973 http://dx.doi.org/10.1128/JB.183.6.1961-1973.2001
9. Banerjee A. K., Arora N., Murty U. S. N. (2009): Structural model of the Plasmodium falciparum Thioredoxin reductase: a novel target for antimalarial drugs. J. Vector Borne Dis. 46, 171-183
10. Becker K., Gromer S., Schirmer R. H., Muller S. (2000): Thioredoxin reductase as a pathophysiological factor and drug target. Eur. J. Biochem. 267, 6118-6125 http://dx.doi.org/10.1046/j.1432-1327.2000.01703.x
11. Björkhem-Bergman L., Jönsson-Videsäter K., Paul Ch., Björnstedt M., Andersson M. (2004): Mammalian thioredoxinreductase alters cytolytic activity of an antibacterial peptide. Peptides 25, 1849-1855 http://dx.doi.org/10.1016/j.peptides.2004.06.012
12. Buchanan B. B., Schurmann P., Decottignies P., Lozano R. M. (1994): Thioredoxin: a multifunctional regulatory protein with a bright future in technology and medicine. Arch. Biochem. Biophys. 314, 257-260 http://dx.doi.org/10.1006/abbi.1994.1439
13. Casagrande S., Bonetto V., Fratelli M., Gianazza E., Eberini I., Massignan T., Salmona M., Chang G., Holmgren A., Ghezzi P. (2002): Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc. Natl. Acad. Sci. USA 99, 9745-9749 http://dx.doi.org/10.1073/pnas.152168599
14. Carvalho C. M. L., Chew E. H., Hashemy S. I., Lu J., Holmgren A. (2008): Inhibition of the human thioredoxin system - a molecular mechanism of mercury toxicity. J. Biol. Chem. 283, 11913-11923 http://dx.doi.org/10.1074/jbc.M710133200
15. Cha M. K., Suh K. H., Kim I. H. (2009): Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J. Exp. Clin. Cancer. Res. 28, 93 http://dx.doi.org/10.1186/1756-9966-28-93
16. Chan J., Xing Y., Magliozzo R. S., Bloom B. R. (1992): Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175, 1111-1122 http://dx.doi.org/10.1084/jem.175.4.1111
17. Chew E. H., Lu J., Bradshaw T. D., Holmgren A. (2008): Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J. 22, 2072-2083 http://dx.doi.org/10.1096/fj.07-101477
18. Cho C. G., Kim H. J., Chung S. W., Jung K. J., Shim K. H., Yu. B. P., Yodoi J., Chung H. Y. (2003): Modulation of glutathione and thioredoxin systems by calorie restriction during the aging process. Exp. Gerontol. 38, 539-548 http://dx.doi.org/10.1016/S0531-5565(03)00005-6
19. Christman M. F., Storz G., Ames B. N. (1989): OxyR, a positive regulator of hydrogen peroxide-inducible genes in Escherichia coli and Salmonella typhimurium, is homologous to afamily of bacterial regulatory proteins. Proc. Nat. Acad. Sci. USA 86, 3484-3488 http://dx.doi.org/10.1073/pnas.86.10.3484
20. Comtois S. L., Gidley M. D., Kelly D. J. (2003): Role of the thioredoxin system and the thiol-peroxidases Tpx and Bcp in mediating resistance to oxidative and nitrosative stress in Helicobacter pylori. Microbiology 149, 121-129 http://dx.doi.org/10.1099/mic.0.25896-0
21. Cox A. G., Brown K. K., Arner E. S., Hampton M. B. (2008): The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem. Pharmacol. 76, 1097-1109 http://dx.doi.org/10.1016/j.bcp.2008.08.021
22. Di Sarra F., Fresch B., Bini R, Saielli G., Bagno A. (2013): Reactivity of auranofin with selenols and thiols implications for the anticancer activity of gold(i) compounds. Eur. J. Inorg. Chem. 15, 2718-2727 http://dx.doi.org/10.1002/ejic.201300058
23. Ejiri S. I., Weissbach H., Brot N. (1979): Reduction of methionine sulfoxide to methionine by Escherichia coli. J. Bacteriol. 139, 161-164
24. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., Poellinger L., Fujii-Kuriyama Y. (1999): Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18, 1905-1914 http://dx.doi.org/10.1093/emboj/18.7.1905
25. Fang J. G., Lu J., Holmgren A. (2005): Thioredoxin reductase is irreversibly modified by curcumin - a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280, 25284-25290 http://dx.doi.org/10.1074/jbc.M414645200
26. Fujiwara N., Fujii T., Fujii J., Taniguchi N. (2001): Roles of N-terminal active cysteines and C-terminal cysteine-selenocysteine in the catalytic mechanism of mammalian thioredoxin reductase. J. Biochem. 129, 803-812 http://dx.doi.org/10.1093/oxfordjournals.jbchem.a002923
27. Gandin V., Fernandes A. P., Rigobello M. P., Dani B., Sorrentino F., Tisato F., Bjornstedt M., Bindoli A., Sturaro A., Rella R., Marzano C. (2010): Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101 http://dx.doi.org/10.1016/j.bcp.2009.07.023
28. Gladyshev V. N., Jeang K. T., Stadtman T. C. (1996): Selenocysteine, identified as the penultimate C-terminal residue in human Tcell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA 93, 6146-6151 http://dx.doi.org/10.1073/pnas.93.12.6146
29. Grogan T. M., Fenoglio-Prieser C., Zeheb R., Bellamy W., Frutiger Y., Vela E., Stemmerman G., Macdonald J., Richter L., Gallegos A., Powis G. (2000): Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol. 31, 475-481 http://dx.doi.org/10.1053/hp.2000.6546
30. Gustafsson T. N., Sandalova T., Lu J., Holmgren A., Schneider G. (2007): Highresolution structures of oxidized and reduced thioredoxin reductase from Helicobacter pylori. Acta Crystallogr., Sect. D: Biol. Crystallogr. 63, 833-843 http://dx.doi.org/10.1107/S0907444907026303
31. Gromer S., Wissing J., Behne D., Ashman K., Schirmer R. H., Flohé L., Becker K. (1998a): A hypothesis on the catalytic mechanism of the selenoenzyme thioredoxin reductase. Biochem. J. 332, 591-592
32. Gromer S., Arscott L. D., Williams C. H. Jr., Schirmer R. H., Becker K. (1998b): Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273, 20096-20101 http://dx.doi.org/10.1074/jbc.273.32.20096
33. Haendeler J., Hoffmann J., Tischler V., Berk B. C., Zeiher A. M., Dimmeler S. (2002): Redox regulatory and anti-apoptotic function of thioredoxin depend on S-nitrosylation at cysteine 69. Nat. Cell. Biol. 4, 743-749 http://dx.doi.org/10.1038/ncb851
34. Han H., Bearss D. J., Browne L. W., Calaluce R., Nagle R. B., Von Hoff D. D. (2002): Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62, 2890-2896
35. Hashemy S. I., Ungerstedt J. S., Zahedi Avval F., Holmgren A. (2006): Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem. 281, 10691-10697 http://dx.doi.org/10.1074/jbc.M511373200
36. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. (1997): AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94, 3633-3638 http://dx.doi.org/10.1073/pnas.94.8.3633
37. Hirt R. P., Müller S., Embley T. M., Coombs G. H. (2002): The diversity and evolution of thioredoxin reductase: new perspectives. Trends Parasitol. 18, 302-308 http://dx.doi.org/10.1016/S1471-4922(02)02293-6
38. Holmgren A. (1985): Thioredoxin. Annu. Rev. Biochem. 54, 237-271 http://dx.doi.org/10.1146/annurev.bi.54.070185.001321
39. Huber H. E., Tabor S., Richardson Ch. C. (1987): Escherichia coli thioredoxin stabilizes complexes of bacteriophage T7 DNA polymerase and primed templates. J. Biol. Chem. 262, 16224-16232
40. Jaeger T., Budde H., Flohe L., Menge U., Singh M., Trujillo M., Radi R. (2004): Multiple thioredoxin-mediated routes to detoxify hydroperoxides in Mycobacterium tuberculosis. Arch. Biochem. Biophys. 423, 182-191 http://dx.doi.org/10.1016/j.abb.2003.11.021
41. Johansson C., Lillig C. H., Holmgren A. (2004): Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. J. Biol. Chem. 279, 7537-7543 http://dx.doi.org/10.1074/jbc.M312719200
42. Lu J., Chew E.-H., Holmgren A. (2007): Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA 104, 12288-12293 http://dx.doi.org/10.1073/pnas.0701549104
43. Kang J.-G., Paget M. S. B., Seok Y.-J., Hahn M.-Y., Bae J.-B., Kleanthous C. (1999): RsrA, an anti-sigma factor regulated by redox change. EMBO J. 18, 4292-4298 http://dx.doi.org/10.1093/emboj/18.15.4292
44. Karlenius T. Ch., Tonissen K. F. (2010): Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation. Cancers 2, 209-232 http://dx.doi.org/10.3390/cancers2020209
45. Kim Y. C., Masutani H., Yamaguchi Y., Itoh K., Yamamoto M., Yodoi J. (2001): Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J. Biol. Chem. 276, 18399-18406 http://dx.doi.org/10.1074/jbc.M100103200
46. Kim H. J., Chae H. Z., Kim Y. J., Kim Y. H., Hwangs T. S., Park E. M., Park Y. M. (2003): Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell. Biol. Toxicol. 19, 285-298 http://dx.doi.org/10.1023/B:CBTO.0000004952.07979.3d
47. Kirkpatrick D. L., Kuperus M., Dowdeswell M., Potier N., Donald L. J., Kunkel M., Berggen M., Angulo M., Powis G. (1998): Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol. 55, 987-994 http://dx.doi.org/10.1016/S0006-2952(97)00597-2
48. Koháryová M., Kollárová M. (2008): Oxidative stress and thioredoxin system. Gen. Physiol. Biophys. 27, 71-84
49. Kosek D., Psenakova K., Rezabkova L., Herman P., Vecer J., Obsilova V., Obsil T. (2014). Biophysical and structural characterization of the thioredoxin-binding domain of protein kinase ASK1 and its interaction with reduced thioredoxin. J. Biol. Chem. 289, 24463-24474 http://dx.doi.org/10.1074/jbc.M114.583807
50. Kunkel M. W., Kirkpatrick D. L., Johnson J. I., Powis G. (1997): Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des. 12, 659-670
51. Laurent T. C., Moore E. C., Reichard P. (1964): Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donnor from E. coli B. J. Biol. Chem. 239, 3436-3444
52. Lee J.-M., Johnson J.A. (2004): An important role of Nrf2-ARE pathway in the celullar defense mechanism. J. Biochem. Mol. Biol. 37, 139-143 http://dx.doi.org/10.5483/BMBRep.2004.37.2.139
53. Liu Z., Du Z. Y., Huang Z. S., Lee K. S., Gu L. Q. (2008): Inhibition of thioredoxin reductase by curcumin analogs. Biosci Biotechnol Biochem 72, 2214-2218 http://dx.doi.org/10.1271/bbb.80229
54. Lu J., Papp L. V., Fang J., Rodriguez-Nieto S., Zhivotovsky B., Holmgren A. (2006): Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quecetin anticancer activity. Cancer. Res 66, 4410-4418 http://dx.doi.org/10.1158/0008-5472.CAN-05-3310
55. Lu J., Holmgren A. (2014): The thioredoxin antioxidant system. Free Radic. Biol. Med. 66, 75-87 http://dx.doi.org/10.1016/j.freeradbiomed.2013.07.036
56. Luo T., Fan T., Liu Y., Rothbart M., Yu J., Zhou S., Grimm B., Luo M. (2012): Thioredoxin redox regulates ATPase activity of magnesium chelatase CHLI subunit and modulates redoxmediated signaling in tetrapyrrole biosynthesis and homeostasis of reactive oxygen species in pea plants. Plant Physiology 159, 118-130 http://dx.doi.org/10.1104/pp.112.195446
57. Luthman M., Holmgren A. (1982): Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 21, 6628-6633 http://dx.doi.org/10.1021/bi00269a003
58. Masutani H., Hirota K., Sasada T., Ueda-Taniguchi Y., Taniguchi Y., Sono H., Yodoi J. (1996): Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I Tax. Immunol. Lett. 54, 67-71 http://dx.doi.org/10.1016/S0165-2478(96)02651-X
59. May J. M., Mendiratta S., Hill K. E., Burk R. F. (1997): Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J. Biol. Chem. 272, 22607-22610 http://dx.doi.org/10.1074/jbc.272.36.22607
60. Mehta M. P., Shapiro W. R., Phan S. C., Gervais R., Carrie C., Chabot P., Patchell R. A., Glantz M. J., Recht L., Langer C. et al. (2009): Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1069-1076 http://dx.doi.org/10.1016/j.ijrobp.2008.05.068
61. Mirabelli C. K., Johnson R. K., Hill D. T., Faucette L. F., Girarg G. R., Kuo G. Y., Sung C. M., Crooke S. T. (1986): Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J. Med. Chem. 29, 218-223 http://dx.doi.org/10.1021/jm00152a009
62. Misra-Press A., McMillan M., Cudaback E., Qabar M., Ruan F., Nguyen M., Vaisar T., Nakanishi H., Kahn M. (2002): Identification of a novel inhibitor of the NF-kB pathway. Curr. Med. Chem. Anti Inflamm. Anti Allergy Agents 1, 29-39 http://dx.doi.org/10.2174/1568014024606566
63. Moi P., Chan K., Asunis I., Cao A., Kan Y. W. (1994): Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/ AP1 repeat of the beta-globin locus control region. PNAS 91, 9926-9930 http://dx.doi.org/10.1073/pnas.91.21.9926
64. Mukherjee A., Westwell A. D., Bradshaw T. D., Stevens M. F. G., Carmichael J., Martin S. G. (2005): Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br. J. Cancer 92, 350-358 http://dx.doi.org/10.1038/sj.bjc.6602338
65. Nakamura H., De Rosa S., Roederer M., Anderson M. T., Dubs J. G., Yodoi J., Holmgren A., Herzenberg L. A. (1996): Elevation of plasma thioredoxin levels in HIV infected individuals. Int. Immunol. 8, 603-611 http://dx.doi.org/10.1093/intimm/8.4.603
66. Nakamura H., Vaage J., Valen G., Padilla C. A., Björnstedt M., Holmgren A. (1998): Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic. Biol. Med. 24, 1176-1186 http://dx.doi.org/10.1016/S0891-5849(97)00429-2
67. Nalvarte I., Damdimopoulos A. E., Spyrou G. (2004): Human mitochondrial thioredoxin reductase reduces cytochrome c and confers resistance to complex III inhibition. Free Radic. Biol. Med. 36. 1270-1278 http://dx.doi.org/10.1016/j.freeradbiomed.2004.02.072
68. Newton G. L., Arnold K., Price M. S., Sherrill C., Delcardayre S. B. Aharonowitz Y., Cohen G., Davies J., Fahey R. C., Davis C. (1996): Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. J. Bacteriol. 178, 1990-1995
69. Nishinaka Y., Masutani H., Nakamura H., Yodoi J. (2001): Regulatory roles of thioredoxin in oxidative stress-induced cellular responses. Redox Rep. 6, 289-295 http://dx.doi.org/10.1179/135100001101536427
70. Nunoshiba T. (1996): Two-stage gene regulation of the superoxide stress response soxRS system in Escherichia coli. Crit. Rev. Eukaryot. Gene Expr. 6, 377-389 http://dx.doi.org/10.1615/CritRevEukarGeneExpr.v6.i4.30
71. Paget M. S. Kang J. G., Roe J. H., Buttner M. J. (1998): δR, an RNA polymerase sigma factor that modulates expression of the thioredoxin system in response to oxidative stress in Streptomyces coelicolor A3 (2). EMBO J. 17, 5776-5782 http://dx.doi.org/10.1093/emboj/17.19.5776
72. Paget M. S., Molle V., Cohen G., Aharonowitz Y., Buttner M. J. (2001): Defining the disulphide stress response in Streptomyces coelicolor A3(2): identification of the sigma R regulon. Mol. Microbiol. 42,1007-1020 http://dx.doi.org/10.1046/j.1365-2958.2001.02675.x
73. Pallis M., Bradshaw T. D., Westwell A. D., Grundy M., Stevens M. F. G., Russell N. (2003): Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. Biochem. Pharmacol. 66, 1695-1705 http://dx.doi.org/10.1016/S0006-2952(03)00471-4
74. Powis G., Kirkpatrick D. L., Angulo M., Baker A. (1998): Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem. Biol. Interact. 111, 23-34 http://dx.doi.org/10.1016/S0009-2797(97)00148-8
75. Powis G., Mustacich D., Coon A. (2000): The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 29, 312-322 http://dx.doi.org/10.1016/S0891-5849(00)00313-0
76. Powis G., Montfort W. R. (2001): Properties and biological activities of thioredoxins. Annu. Rev. Pharmacol. Toxicol. 41, 261-295 http://dx.doi.org/10.1146/annurev.pharmtox.41.1.261
77. Pieters J. (2008): Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3, 399-407 http://dx.doi.org/10.1016/j.chom.2008.05.006
78. Raffel J., Bhattacharyya A. K., Gallegos A., Cui H. Einspahr J. G., Alberts D. S., Powis G. (2003): Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 142, 46-51 http://dx.doi.org/10.1016/S0022-2143(03)00068-4
79. Raman K., Yeturu K., Chandra N. (2008): targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis. BMC Syst. Biol. 2, 109 http://dx.doi.org/10.1186/1752-0509-2-109
80. Reott M. A., Parker A. C., Rocha E. R., Smith C. J. (2009): Thioredoxins in redox maintenance and survival during oxidative stress of Bacteroides fragilis. J. Bacteriol. 191, 3384-3391 http://dx.doi.org/10.1128/JB.01665-08
81. Rich E. A., Torres M., Sada E., Finegan C. K., Hamilton B. D., Toossi Z. (1997): Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuber. Lung Dis. 78, 247-255 http://dx.doi.org/10.1016/S0962-8479(97)90005-8
82. Rigobello M. P., Messori L., Marcon G., Agostina Cinellu M., Bragadin M., Folda A., Scutari G., Bindoli A. (2004): Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J. Inorg. Biochem. 98, 1634-1641 http://dx.doi.org/10.1016/j.jinorgbio.2004.04.020
83. Rocha E. R., Tzianabos A. O., Smith C. J. (2007): Thioredoxin reductase is essential for thiol/disulfide redox control and oxidative stress survival of the anaerobe Bacteroides fragilis. J. Bacteriol. 189, 8015-8023 http://dx.doi.org/10.1128/JB.00714-07
84. Ross J. A., Kasum C. M. (2002): Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 22, 19-34 http://dx.doi.org/10.1146/annurev.nutr.22.111401.144957
85. Rubartelli A., Bonifaci N., Sitia R. (1995): High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res. 55, 675-680
86. Ryan K. J., Ray C. G (2004): Sherris Medical Microbiology (4th ed.). McGraw Hill
87. Saito I., Shimuta M., Terauchi K., Tsubota K., Yodoi J., Miyasaka N. (1996): Increased expression of human thioredoxin/adult T cell leukemia-derived factor in Sjogren's syndrome. Arthritis Rheum. 39, 773-782 http://dx.doi.org/10.1002/art.1780390509
88. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. (1998): Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17, 2596-2606 http://dx.doi.org/10.1093/emboj/17.9.2596
89. Sasada T., Iwata S., Sato N., Kitaoka Y., Hirota K., Nakamura K., Nishiyama A., Taniguchi Y., Takabayashi A., Yodoi J. (1996): Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest. 97, 2268-2276 http://dx.doi.org/10.1172/JCI118668
90. Sasada T., Nakamura H., Ueda S., Sato N., Kitaoka Y., Gon Y., Takabayashi A., Spyrou G., Holmgren A., Yodoi J. (1999): Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 27, 504-514 http://dx.doi.org/10.1016/S0891-5849(99)00101-X
91. Selenius M., Hedman M., Brodin D., Gandin V., Rigobello M. P., Flygare J., Marzano C. H., Bindoli A., Brodin O., Bjornstedt M., Fernandes A. P. (2012): J. Cell. Mol. Med. 16, 1593-1605 http://dx.doi.org/10.1111/j.1582-4934.2011.01469.x
92. Scharf C., Riethdorf S., Ernst H., Engelmann S., Volker U., Hecker M. (1998): Thioredoxin is an essential protein induced by multiple stresses in Bacillus subtilis. J. Bacteriol. 180, 1869-1877
93. Schweizer U., Brauer A. U., Kohrle J., Nitsch R., Savaskan N. E. (2004): Selenium and brain function: a poorly recognized liaison. Brain Res. Rev. 45, 164-178 http://dx.doi.org/10.1016/j.brainresrev.2004.03.004
94. Shaw C. F. (1999): Gold-based therapeutic agents. Chem. Rev. 99, 2589-2600 http://dx.doi.org/10.1021/cr980431o
95. Shinnick T. M., King H., Quinn F. D. (1995): Molecular biology, virulence, and pathogenicity of mycobacteria. Am. J. Med. Sci. 309, 92-98 http://dx.doi.org/10.1097/00000441-199502000-00008
96. Smart D., Ortiz K., Mattson D., Bradbury C. M., Bisht K. S., Sieck L. K., Brechbiel M. W., Gius D. (2004): Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res. 64, 6716-6724 http://dx.doi.org/10.1158/0008-5472.CAN-03-3990
97. Sorrentino F., Karioti A., Gratteri P., Rigobello M. P., Scutari G., Messori L., Bindoli A., Chioccioli M., Gabbiani Ch., Bergonzi M. C., Bilia A. R. (2011): Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones. Bioorg. Med. Chem. 19, 631-641 http://dx.doi.org/10.1016/j.bmc.2010.10.045
98. Söderberg A., Sahaf B., Rosn A. (2000): Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res. 60, 2281-2289
99. Sumida S., Nakamura H., Yodoi J. (2004): Thioredoxin induction of peripheral blood mononuclear cells in mice in response to a single bout of swimming exercise. Gen. Physiol. Biophys. 23, 241-249
100. Sun Q. A., Su D., Novoselov S. V., Carlson B. A., Hatfield D. L., Gladyshev V. N. (2005): Reaction mechanism and regulation of mammalian thioredoxin/glutathione reductase. Biochemistry 44, 14528-14537 http://dx.doi.org/10.1021/bi051321w
101. Sund C. J., Rocha E. R., Tzianabos A. O., Wells W. G., Gee J. M., Reott M. A., O'Rourke D. P., Smith C. J. (2008): The Bacteroides fragilis transcriptome response to oxygen and H2O2: the role of OxyR and its effect on survival and virulence. Mol. Microbiol. 67, 129-142 http://dx.doi.org/10.1111/j.1365-2958.2007.06031.x
102. Štefanková P., Kollárová M., Barák I. (2005): Thioredoxin - structural and functional complexity. Gen. Physiol. Biophys. 24, 3-11
103. Tally F. P., Jacobus N. V., Bartlett J. G., Gorbach S. L. (1975): In vitro activity of penicillins against anaerobes. Antimicrob. Agents Chemother. 7, 413-414 http://dx.doi.org/10.1128/AAC.7.4.413
104. Tamura T., Stadtman T. C. (1996): A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA 93, 1006-1011 http://dx.doi.org/10.1073/pnas.93.3.1006
105. Tanudji M., Hevi S., Chuck S. L. (2003): The nonclassic secretion of thioredoxin is not sensitive to redox state. Am. J. Physiol. Cell Physiol. 284, C1272-1279 http://dx.doi.org/10.1152/ajpcell.00521.2002
106. Tao K., Fujita N., Ishihama A. (1993): Involvement of the RNA polymerase alpha subunit C-terminal region in co-operative interaction and transcriptional activation with OxyR protein. Mol. Microbiol. 7, 859-864 http://dx.doi.org/10.1111/j.1365-2958.1993.tb01176.x
107. Tao L., Jiao X., Gao E., Lau W. B., Yuan Y., Lopez B., Christopher T., Ramachandrarao S. P., Williams W., Southan G., Sharma K., Koch W., Ma X. L. (2006): Nitrative inactivation of thioredoxin- 1 and its role in postischemic myocardial apoptosis. Circulation 114, 1395-1402 http://dx.doi.org/10.1161/CIRCULATIONAHA.106.625061
108. Tonissen K. F., Di Trapani G. (2009): Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res. 53, 87-103 http://dx.doi.org/10.1002/mnfr.200700492
109. Tsang M. L., Schiff J. A. (1976): Sulfate-reducing pathway in Escherichia coli involving bound intermediates. J. Bacteriol. 125, 923-933
110. Uziel O., Borovok I., Schreiber R., Cohen G., Aharonowitz Y. (2004): Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J. Bacteriol. 186, 326-334 http://dx.doi.org/10.1128/JB.186.2.326-334.2004
111. Varsik P., Buranova D., Kollar B., Fedor-Freybergh P. G. (2006): Metabolic stroke in the three years old boy as acosequence of metabolic derangement. A case report of recidiving Reye's-like syndrome. Neuro. Endocrinol. Lett. 27, 13-15
112. Wagner C., Sudati J. H., Nogueira C. W., Rocha J. B. (2010): In vivo and in vitro inhibition of mice thioredoxin reductase by methylmercury. Biometals 23, 1171-1177 http://dx.doi.org/10.1007/s10534-010-9367-4
113. Watson W. H., Jones D. P. (2003): Oxidation of nuclear thioredoxin during oxidative stress. FEBS Lett. 543, 144-147 http://dx.doi.org/10.1016/S0014-5793(03)00430-7
114. Welsh S. J., Williams R. R., Birmingham A., Newman D. J., Kirkpatrick D. L., Powis G. (2003): The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol. Cancer Ther. 2, 235-243
115. Wieles B., van Noort J., Drijfhout J. W., Offringa R., Holmgren A., Ottenhoff T. H. (1995): Purification and functional analysis of the Mycobacterium leprae thioredoxin/thioredoxin reductase hybrid protein. J. Biol. Chem. 270, 25604-25606 http://dx.doi.org/10.1074/jbc.270.43.25604
116. Williams C. H. Jr. (1992): Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase, and mercuric ion reductase - a family of flavoenzyme transhydrogenases. In: Chemistry and Biochemistry of Flavoenzymes. (Ed. F.Müller), pp. 121-211, CRC Press, Boca Raton
117. Williams C. H. Jr., Arscott L. D., Müller S., Lennon B. W., Ludwig M. L., Wang P. F., Veine D. M., Becker K. (2000): Thioredoxin reductase. Two models of catalysis have evolved. Eur. J. Biochem. 267, 6110-6117 http://dx.doi.org/10.1046/j.1432-1327.2000.01702.x
118. Williams R. J., Spencer J. P., Rice-Evans C. (2004): Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med. 36, 838-849 http://dx.doi.org/10.1016/j.freeradbiomed.2004.01.001
119. Wipf P., Hopkins T. D., Jung J.-K., Rodriguez S., Birmingham A., Southwick E. C., Lazo J. S., Powis G. (2001): New inhibitors of the thioredoxin-thioredoxin reductase system based on a napthoquinone spiroketal natural product lead. Bioorg. Med. Chem. Lett. 11, 2637-2641 http://dx.doi.org/10.1016/S0960-894X(01)00525-X
120. Witte A. B., Anestal K., Jerremalm E., Ehrsson H., Arner E. S. (2005): Inhibition of thioredoxin reductase but not glutathione reductase by the major classess of alkylating and platinumcontaining anticancer compounds. Free Radic. Biol. Med. 39, 696-703 http://dx.doi.org/10.1016/j.freeradbiomed.2005.04.025
121. Xia L., Nordman T., Olsson J. M., Damdimopoulos A., Bjorkhem- Bergman L., Nalvarte I., Eriksson L. C., Arner E. S., Spyrou G., Bjornstedt M. (2003): The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J. Biol. Chem. 278, 2141-2146 http://dx.doi.org/10.1074/jbc.M210456200
122. Yang C. S., Landau J. M., Huang M. T., Newmark H. L. (2001): Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 21, 381-406 http://dx.doi.org/10.1146/annurev.nutr.21.1.381
123. Yang L., Yijing L., Shenghui Y., Gusen Z. (2012): Recent advanced in development of thioredoxin reductase inhibitors as anticancer agents. Curr. Drug Targets 13, 1432-1444 http://dx.doi.org/10.2174/138945012803530224
124. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., Kohno K. (1995): Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Research 55, 4293-4296
125. Yoshida S., Katoh T., Tetsuka T., Uno K., Matsui N., Okamoto T. (1999): Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J. Immunol. 163, 351-358
126. Young L. D., Darryl Y., Bateman R. M., Brock G. B. (2004): Oxidative stress and antioxidant therapy: their impact in diabetesassociated erectile dysfunction. J. Androl. 25, 830-836
127. Yuan Y., Jiao X., Lau W. B., Wang Y., Christopher T. A., Lopez B. L., RamachandraRao S. P., Tao L., Ma X.-L. (2010): Thioredoxin glycation: a novel posttranslational modification that inhibits its antioxidant and organ protective actions. Free Radic. Biol. Med. 49, 332-338 http://dx.doi.org/10.1016/j.freeradbiomed.2010.04.017
128. Zhang Y. Z., Gould K. L., Dunbrack R. L. Jr., Cheng H., Roder H., Golemis E. A. (1999): The evolutionarily conserved Dim1 protein defines a novel branch of the thioredoxin fold superfamily. Physiol. Genomics 1, 109-118
129. Zhong L., Du Z. Y., Huang Z. S., Lee K. L., Gu L. Q. (2008): Inhibition of thioredoxin reductase by curcumin alanogs. Biosci. Biotechnol. Biochem. 72, 2214-2218 http://dx.doi.org/10.1271/bbb.80229